Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Price, Quote, News and Overview

NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD

1.53  -0.05 (-3.16%)

ADAG Quote, Performance and Key Statistics

ADAGENE INC-ADR

NASDAQ:ADAG (4/17/2025, 8:00:48 PM)

1.53

-0.05 (-3.16%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.58
52 Week Low1.33
Market Cap72.08M
Shares47.11M
Float31.75M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-23 2025-07-23
IPO02-09 2021-02-09


ADAG short term performance overview.The bars show the price performance of ADAG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

ADAG long term performance overview.The bars show the price performance of ADAG in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40

The current stock price of ADAG is 1.53 USD. In the past month the price decreased by -14.04%. In the past year, price decreased by -42.05%.

ADAGENE INC-ADR / ADAG Daily stock chart

ADAG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.23B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.88B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About ADAG

Company Profile

ADAG logo image Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 174 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Company Info

ADAGENE INC-ADR

4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park

Suzhou JIANGSU 215123 CN

CEO: Peter (Peizhi) Luo

Employees: 174

Company Website: https://www.adagene.com/

Investor Relations: http://www.investor.adagene.com/

Phone: 8651287773632

ADAGENE INC-ADR / ADAG FAQ

What is the stock price of ADAGENE INC-ADR today?

The current stock price of ADAG is 1.53 USD. The price decreased by -3.16% in the last trading session.


What is the ticker symbol for ADAGENE INC-ADR stock?

The exchange symbol of ADAGENE INC-ADR is ADAG and it is listed on the Nasdaq exchange.


On which exchange is ADAG stock listed?

ADAG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ADAGENE INC-ADR stock?

9 analysts have analysed ADAG and the average price target is 10.31 USD. This implies a price increase of 573.56% is expected in the next year compared to the current price of 1.53. Check the ADAGENE INC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ADAGENE INC-ADR worth?

ADAGENE INC-ADR (ADAG) has a market capitalization of 72.08M USD. This makes ADAG a Micro Cap stock.


How many employees does ADAGENE INC-ADR have?

ADAGENE INC-ADR (ADAG) currently has 174 employees.


What are the support and resistance levels for ADAGENE INC-ADR (ADAG) stock?

ADAGENE INC-ADR (ADAG) has a support level at 1.52 and a resistance level at 1.59. Check the full technical report for a detailed analysis of ADAG support and resistance levels.


Is ADAGENE INC-ADR (ADAG) expected to grow?

The Revenue of ADAGENE INC-ADR (ADAG) is expected to decline by -27.93% in the next year. Check the estimates tab for more information on the ADAG EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ADAGENE INC-ADR (ADAG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ADAGENE INC-ADR (ADAG) stock pay dividends?

ADAG does not pay a dividend.


When does ADAGENE INC-ADR (ADAG) report earnings?

ADAGENE INC-ADR (ADAG) will report earnings on 2025-07-23.


What is the Price/Earnings (PE) ratio of ADAGENE INC-ADR (ADAG)?

ADAGENE INC-ADR (ADAG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).


What is the Short Interest ratio of ADAGENE INC-ADR (ADAG) stock?

The outstanding short interest for ADAGENE INC-ADR (ADAG) is 0.06% of its float. Check the ownership tab for more information on the ADAG short interest.


ADAG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ADAG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ADAG. Both the profitability and financial health of ADAG have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ADAG Financial Highlights

Over the last trailing twelve months ADAG reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS decreased by -71.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -37.44%
ROE -66.16%
Debt/Equity 0.1
Chartmill High Growth Momentum
EPS Q2Q%-5.81%
Sales Q2Q%-87.35%
EPS 1Y (TTM)-71.88%
Revenue 1Y (TTM)-99.43%

ADAG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to ADAG. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -16.1% and a revenue growth -27.93% for ADAG


Ownership
Inst Owners23.94%
Ins Owners3.25%
Short Float %0.06%
Short Ratio0.24
Analysts
Analysts77.78
Price Target10.31 (573.86%)
EPS Next Y-16.1%
Revenue Next Year-27.93%